| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Recent advancements in clinical data have showcased Eli Lilly's significant progress in drug development, particularly in the obesity and eczema treatment sectors. The efficacy of drugs like EBGLYSS and novel GLP-1 class medications emphasize the company's innovative approach and ability to provide improved patient outcomes. Enhanced focus on next-generation therapies positions Eli Lilly as a competitive player in the pharmaceutical market, especially for pediatric and diabetic populations. Ongoing developments in drug innovation continue to solidify the company's reputation for excellence in product/service development. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -2.4 is extremely bearish. The market sentiment at -0.5 is modestly bearish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move down since both trend sentiment and market sentiment are negative. The positive sentiment force for sector is at 0.3, and the negative at -0.8 on 2026-03-19. The forces of Stock Price Trend (-2.4), Valuation Sentiment (-1.7), and Sector Price Trend (-1.4) will drive down the price. The forces of Market Risk Appetite (0), Sentiment towards Fundamentals (0.2), Option Sentiment (0.8), and Price Level Sentiment (1) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | 0%(0.1%) | 917.68 | 4.17% | -2 | -0.03% | -0.66% | -2.4 | -0.5 | 1.7% | -0.5 | Short | 70% | 0.2 | 5.8 |
| 2026-03-18 | 0%(0.1%) | 917.93 | 3.7% | -12 | -1.35% | -0.86% | -3.1 | -0.5 | 3.3% | -0.7 | Short | 70% | -1.6 | 4 |
| 2026-03-17 | 1%(0.1%) | 930.51 | 3.02% | -18 | -5.89% | -0.77% | -2.7 | -1.5 | 2.5% | -0.3 | Short | 60% | -0.4 | -5.6 |
| 2026-03-16 | 0%(0%) | 988.79 | 2.28% | 23 | 0.34% | -0.28% | -1 | 0.2 | 0.6% | 0.3 | Wait | 50% | 2.2 | -5 |
| 2026-03-15 | 0%(0%) | -1.1 | 0.2 | 0.5 | 1.7 | -1 | ||||||||
| 2026-03-14 | 0%(0%) | -1.1 | 0.2 | 0.4 | 1.5 | -1 | ||||||||
| 2026-03-13 | 0%(0%) | 985.42 | 2.29% | 17 | 0.9% | -0.67% | -1.1 | -0 | 0.8% | 0.7 | Short | 55% | 1.9 | 7 |
| 2026-03-12 | 0%(0%) | 976.64 | 2.26% | 3 | -2.3% | -0.45% | -0.8 | -0.4 | 1.1% | 0.5 | Wait | 50% | 1.3 | -4 |
| 2026-03-11 | 0%(0%) | 999.61 | 1.99% | 25 | -0.17% | -0.3% | -0.5 | 0.1 | 0.4% | 0.3 | Wait | 50% | 2.5 | 6.5 |
| 2026-03-10 | 0%(0%) | 1001.3 | 1.94% | 24 | -0.68% | -0.41% | -0.7 | 0.2 | 0.9% | 0.5 | Wait | 50% | 1.5 | -1 |
| Short is the preferred trading strategy with 70% chance of being right. Both trend sentiment and hourly trend are very weak. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-03-19 17:02:08 The financial performance of companies like Eli Lilly is closely watched by investors, particularly as their products gain approval and uptake in the market. |
| 2026-03-19 17:02:08 Studies showing positive patient outcomes from Eli Lilly's obesity drug enhance its appeal and market viability. |
| 2026-03-19 17:02:08 Eli Lilly and Vertex Pharmaceuticals are part of a competitive environment where their respective products are vying for market share in obesity and diabetes treatment. |
| 2026-03-19 17:02:08 The development of the next-generation obesity drug retatrutide signals significant advancements in treatment options for Type 2 diabetes and weight management. |
| 2026-03-19 17:02:08 Eli Lilly demonstrates strong growth potential through its leadership in the weight loss market and effective pharmaceutical products. |
| 2026-03-19 13:49:12 Eli Lilly faces increasing competition in the diabetes treatment market, as new therapies are developed and marketed by other pharmaceutical companies. |
| 2026-03-19 13:49:12 The effectiveness of Eli Lilly’s experimental diabetes shot in achieving significant weight loss positions it strongly against competitors in the diabetes medication landscape. |
| 2026-03-19 13:49:12 The articles highlight Eli Lilly's advancements in diabetic treatments through innovative drugs, showcasing their potential in the pharmaceutical market. |
| 2026-03-19 09:34:49 The intense competition among pharmaceutical companies in the obesity drug market, focusing on innovation and efficacy to capture market share. |
| 2026-03-19 09:34:49 The development of next-generation obesity drugs, specifically the breakthroughs in the GLP-1 drug class, as companies aim to improve treatment options. |